Home › Langerhans-Cell Histiocytosis
Langerhans-Cell Histiocytosis clinical trials recruiting in the U.S.
8 studies for Langerhans-Cell Histiocytosis are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
RecruitingPhase 2
180 Days – 22 Years · All sexes · Updated Sep 29, 2026 · NCT05828069Mirdametinib in Histiocytic Disorders
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Sep 21, 2026 · NCT06153173Histiocytic Disorder Follow-up Study
RecruitingObservational study
Ages 0 to 89 · All sexes · Updated Jun 12, 2026 · NCT05915208Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Apr 7, 2026 · NCT06582745Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT03329274Q702 for the Treatment of Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RecruitingPhase 2
All ages · All sexes · Updated Sep 18, 2025 · NCT04079179Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
RecruitingPhase 3
Up to age 21 · All sexes · Updated Sep 11, 2025 · NCT02670707From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.